fbpx
Loading
  • Twitter
  • Linkedin
  • Facebook
  • Gplus
  • Mail
  • Rss
  • Login
    • Password Reset
  • Register
(852) 3008 1717
Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong Kong
  • Health
  • Medical Writing
  • Digital Marketing
  • Competitive Pricing
  • Contact Us
  • Search
  • Menu
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share by Mail

May 2018, San Diego, CA

CICS Immuno Oncology Annual Meeting

About the Meeting

MediPaper is proud to be an official sponsor of the CICS Immuno Oncology Annual Meeting 2017.

The CICS Annual Conference on Immuno Oncology is offering the most significant advances in the world of oncology.

The goal of the meeting is to convey the clinical and translational advances in various areas of cancer immunology to medical oncologists, medical students, and other health professionals.

Join CICS and a panel of experts in San Diego, CA., for a leading event in immunooncology.

The CICS ImmunoOncology Annual Meeting 2018

Website

Meeting Objectives

  • Coming Soon

Workshops

  • Coming Soon.

Faculty

Organising Committee

  • Juan Pablo Marquez Manriquez, MD
    CICS, Seattle, WA, USA
  • Pedro Lucero Diaz, MD
    CICS, Ciudad Obregon, Sonora, Mexico
  • Gardenia Vargas Parra, MD
    CICS, Seattle, WA, USA

Invited Speakers

  • Esteban Celis, MD, PhD
    Georgia Cancer Center, USA
  • Brad Nelson, PhD
    British Columbia Cancer Agency, Victoria, Canada
  • Suzanne Ostrand-Rosenberg, PhD
    University of Maryland, Baltimore, USA
  • Elizabeth Repasky, PhD
    Roswell Park Cancer Center Institute, USA
  • Yasmin Thanavala, MD
    Roswell Park Cancer Center Institute, USA
  • Jose Antonio Matute Briseno, MD
    CICS, Ciudad Obregon, Sonora, Mexico

Location

Maps were disabled by the visitor on this site.
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share by Mail

YOU MAY ALSO LIKE

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer©pixologic / 123rf stock photo

U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 19-Jun-2018

/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-07-19 23:00:012018-07-20 10:42:05U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 19-Jun-2018
ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower©eraxion / 123RF Stock Photo

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

/wp-content/uploads/2018/06/ASCO-2018-nsclc-immunotherapy-ASCO18-lung-cancer-pembrolizumab-avelumab-nivolumab-duravalumab-ipilimumab-osimertinib-dacomitinib-lorlatinib-crizotinib-alectinib-keytruda-KEYNOTE-CheckMate-JAVELIN-IMpower.jpg 1000 1500 Anne John Michael /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Anne John Michael2018-06-25 18:22:252018-07-06 06:15:22ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised
ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo©eraxion / 123RF Stock Photo

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

/wp-content/uploads/2018/06/ASCO-2018-breast-cancer-TNBC-MBC-ABC-ASCO18-PHEREXA-D-CARE-ABCSG-18-ASTRRA-TEXT-SOFT-MONARCH-2-MONALEESA-3-SANDPIPER-BOLERO-6-TOPACIO-KEYNOTE-162-TONIC-TOPACIO-GeparNeuvo.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-06-19 09:02:512018-06-19 23:57:08ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2© krishnacreations / 123RF Stock Photo

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

/wp-content/uploads/2018/06/ASCO18-ASCO-2018-HCC-hepatocellular-carcinoma-liver-cancer-pembrolizumab-KEYTRUDA-atezolizumab-TECENTRIQ-PD-1-PD-L1-immunecheckpoint-immunotherapy-ramucirumab-cabozantinib-KEYNOTE-224-SCRUM-Japan-GI-SCREEN-CELESTIAL-REACH-2.jpg 1000 1500 Anne John Michael /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Anne John Michael2018-06-08 11:59:542018-06-12 00:44:39ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised
IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclcbravajulia / 123RF Stock Photo

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

/wp-content/uploads/2018/05/IMPower150-Reck-Socinski-ELCC-AACR-2018-firstline-atezolizumab-bevacizumab-chemotherapy-non-squamous-nsclc.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-05-10 16:19:462018-05-24 09:31:31AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC
US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

US FDA approved CAR-T cell and BiTE immunotherapy - Updated 2-May-2018

/wp-content/uploads/2018/04/US-FDA-approved-CAR-t-cell-BiTE-DAR-T-cell-CD19-Immunotherapies-blinatumomab-axicabtagene-ciloleucel-tisagenlecleucel.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-05-02 10:00:352018-05-24 09:36:21US FDA approved CAR-T cell and BiTE immunotherapy - Updated 2-May-2018
AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826Hywards / 123RF Stock Photo

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

/wp-content/uploads/2018/04/First-line-Nivolumab-Ipilimumab-in-TMB-high-NSCLC-front-line-immunotherapy-for-non-small-cell-lung-cancer-CheckMate-227-NCT02477826.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-04-21 10:30:432018-05-24 09:37:03Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)
NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhikrishnacreations / 123RF Stock Photo

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

/wp-content/uploads/2018/04/NCT02578680-Keynote189-pembrolizumab-chemotherapy-nsclc-NEJM-Leena-Gandhi.jpg 938 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-04-19 01:27:262018-05-24 09:37:16Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC
Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

/wp-content/uploads/2018/04/Keynote-042-Keynote-024-pembrolizumab-nsclc-keytruda-nsclc-non-squamous-squamous-PD-L1-expression-1-20-50-Tony-Mok-MD-NCT02220894-Pembrolizumab-effective-in-frontline-NSCLC-with-low-PD-L1-expression.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-04-10 20:15:112018-05-24 09:37:32Pembrolizumab effective in frontline NSCLC with low PD-L1 expression
Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

/wp-content/uploads/2018/02/Herbert-Loong-on-irAEs-Immunotherapy-I-O-and-New-Onset-Diabetes-or-immune-mediated-diabetes.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-04-06 09:00:412018-05-24 09:38:20I-O in Special Populations: Diabetes and Concomitant Steroids
Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

/wp-content/uploads/2018/04/Crizotinib-beneficial-for-East-Asian-NSCLC-patients-with-ROS1-alterations-crizotinib-asian-crizotinib-ros1-crizotinib-asian-nsclc-patients-crizotinib-asian-non-small-cell-lung-cancer-patients-e1522913753323.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-04-04 16:00:112018-04-19 13:57:57Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations
immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

/wp-content/uploads/2018/03/nivolumab-npc-opdivo-nasopharyngeal-carcinoma-brigette-ma-CUHK-phase-II-nci-9742-study-JCO-journal-of-clinical-oncology.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-03-31 09:20:312018-05-24 09:38:41Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)
Making sense of immunotherapy in NSCLC

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

/wp-content/uploads/2018/03/Making-sense-of-immunotherapy-in-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-03-26 16:06:282018-05-10 16:25:39Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)
Symposium Highlight 5HT3 NK1 Palonosetron Netupitant CINV Chemotherapy-induced Nausea and Vomiting

Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control

/wp-content/uploads/2018/01/Symposium-Highlight-5HT3-NK1-Palonosetron-Netupitant-CINV-Chemotherapy-induced-Nausea-and-Vomiting-.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-01-30 00:36:322018-04-19 13:57:19Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control
manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

/wp-content/uploads/2017/11/image.png 852 1471 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-29 22:12:232018-04-19 10:46:51Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects
ASPEN CSA 2017 Prof Xue Zhanggang on TIVA Enhanced Recovery by Optimized Anesthetics

TIVA: enhanced recovery by optimized anesthetics

/wp-content/uploads/2017/11/ASPEN-CSA-2017-Prof-Xue-Zhanggang-on-TIVA-Enhanced-Recovery-by-Optimized-Anesthetics.jpeg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-23 16:06:422018-05-11 10:27:20TIVA: enhanced recovery by optimized anesthetics
2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

Do you know your lifetime risk on Pancreatic Cancer?

/wp-content/uploads/2016/11/2016-Pancreatic-Cancer-medipaper-medical-communications-medical-writer-hire-healthcare-writers-hong-kong.jpg 844 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-20 12:29:422018-02-09 14:08:00Do you know your lifetime risk on Pancreatic Cancer?
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China

/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.jpg 687 1030 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-07 22:23:132018-05-11 10:27:33CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Xiong Lize on the status of ERAS in China

/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.png 687 1030 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-11-07 20:54:572018-05-11 10:27:41CSA2017: Prof Xiong Lize on the status of ERAS in China
HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

/wp-content/uploads/2017/10/HKBCF-luminal-breast-cancer-can-cdk46-inhibition-by-palbociclib-improve-on-chemotherapy-medipaper-medical-writer-hong-kong.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-10-25 22:58:382018-02-09 14:08:00Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

/wp-content/uploads/2017/09/Nivolumab-Renal-Cell-Cancer-Symposium-Highlight.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-09-19 23:04:512018-06-20 21:37:49Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of AnaesthesiologyCSA 2017

25th Annual Meeting of the Chinese Society of Anaesthesiology

/wp-content/uploads/2017/09/CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology.png 684 845 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-09-06 18:03:272018-05-11 10:15:3625th Annual Meeting of the Chinese Society of Anaesthesiology
pharma digital marketing

Pharma Digital Marketing: Lackluster or Blockbuster?

/wp-content/uploads/2017/08/pharma-digital-marketing-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-08-07 00:51:472018-02-09 13:51:12Pharma Digital Marketing: Lackluster or Blockbuster?
adjuvant hormonal therapy

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

/wp-content/uploads/2017/08/adjuvant-hormonal-therapy.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2017-07-05 22:46:312018-02-09 14:08:00Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?
AMNOG Germany Pharmaceuticals Pricing Legislation MediPaper Medical Writer Hong Kong

AMNOG: Germany Pharmaceuticals Pricing Legislation Overview

/wp-content/uploads/2016/12/AMNOG-Germany-Pharmaceuticals-Pricing-Legislation-MediPaper-Medical-Writer-Hong-Kong.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-12-15 15:12:092018-02-09 13:51:11AMNOG: Germany Pharmaceuticals Pricing Legislation Overview
esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

/wp-content/uploads/2016/10/ESMO-2016-Breast-Cancer-Palbociclib-Ribociclib-Abemaciclib-data-MediPaper-Medical-Writer-e1478671413852.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-11-09 16:00:442018-05-11 17:14:06ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

/wp-content/uploads/2016/08/PD-L1-Biomarker-for-Response-DAKO-22C3-MediPaper-Medical-Communications.png 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-26 14:00:352018-05-11 17:21:18PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data
Biomarkers Ipilimumab Treatment MediPaper Medical Communications

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

/wp-content/uploads/2016/10/Biomarkers-Ipilimumab-Treatment-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-24 10:12:072018-05-11 17:18:58Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies
ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data - Download the PPT

/wp-content/uploads/2016/09/ESMO-2016-ipilimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-11 11:10:102018-05-11 17:28:19ESMO16 Ipilimumab data - Download the PPT
ESMO 2016 pembrolizumab data medipaper medical communications

ESMO16 Pembrolizumab data - Download the PPT

/wp-content/uploads/2016/09/ESMO-2016-pembrolizumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-10 21:08:122018-05-11 17:28:28ESMO16 Pembrolizumab data - Download the PPT
ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

ESMO16 Durvalumab, Avelumab, Tremelimumab Data - Download the PPT

/wp-content/uploads/2016/10/ESMO-2016-durvalumab-avelumab-tremelimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-10 10:30:512018-05-11 17:28:38ESMO16 Durvalumab, Avelumab, Tremelimumab Data - Download the PPT
ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data - Download the PPT

/wp-content/uploads/2016/09/ESMO-2016-atezolizumab-data-medipaper.jpg 665 1000 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-09 17:50:232018-05-11 17:28:52ESMO16 Atezolizumab data - Download the PPT
ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data - Download the PPT

/wp-content/uploads/2016/09/ESMO-2016-nivolumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-10-09 16:30:582018-05-11 17:29:00ESMO16 Nivolumab data - Download the PPT
cancer awareness improves outcome medipaper medical communications

Cancer symptom awareness linked to survival

/wp-content/uploads/2016/09/cancer-awareness-improves-outcome-medipaper-medical-communications.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-09-30 21:33:432018-02-09 13:51:10Cancer symptom awareness linked to survival
2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

/wp-content/uploads/2016/09/2016-asco-ovarian-cancer-guidelines-neo-adjuvant-chemotherapy-medipaper-medical-communications-e1478394814429.png 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-09-27 21:53:422018-02-09 14:07:58ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated
IMM-101 plus gemcitabine-medipaper medical communications BW

IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

/wp-content/uploads/2016/09/IMM-101-plus-gemcitabine-medipaper-medical-communications_medical_writer_hong_kong.jpg 844 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-09-25 00:19:582018-02-09 13:51:09IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer
palbociclib-first-in-class

Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

/wp-content/uploads/2016/04/palbociclib-first-in-class.jpg 662 1095 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-09-17 00:46:162018-05-11 17:13:52Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor
Ki67 breast cancer medical writer epotomics

Ki67 in Breast Cancer: an overview

/wp-content/uploads/2016/04/Ki67-breast-cancer-medical-writer-epotomics-com.png 998 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-09-06 00:07:072018-05-11 17:15:08Ki67 in Breast Cancer: an overview
ASCO 2016 ribociclib & abemaciclib Data - MediPaper Medical Communications

ASCO16 Ribociclib & Abemaciclib Data

/wp-content/uploads/2016/06/ribociclib-abemaciclib-ASCO2016-Data-MediPaper-Medical-Communications.jpg 1033 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-06-05 23:30:482018-05-11 17:17:01ASCO16 Ribociclib & Abemaciclib Data
ASCO 2016 Palbociclib Data MediPaper Medical Communications

ASCO16 palbociclib (Ibrance©) Data

/wp-content/uploads/2016/06/ASCO-2016-Palbociclib-Data-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-06-04 22:51:302018-05-11 17:16:17ASCO16 palbociclib (Ibrance©) Data
ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

/wp-content/uploads/2016/06/ASCO-2016-Azelumab-Durvalumab-and-Tremelimumab-Data.jpg 938 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-06-03 11:57:432018-05-11 17:25:17ASCO16 Avelumab, Durvalumab, and Tremelimumab
asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

/wp-content/uploads/2016/06/asco-2016-atezolizumab-data.jpg 1200 1800 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-06-02 15:15:132018-05-11 17:25:04ASCO16 Atezolizumab (Tecentriq©) Data
ASCO2016 ipilimumab data - MediPaper Medical Communications

ASCO16 Ipilimumab (Yervoy©) Data

/wp-content/uploads/2016/05/ASCO2016-ipilimumab-data-MediPaper-Medical-Communications.jpg 938 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-05-31 13:05:442018-05-11 17:22:00ASCO16 Ipilimumab (Yervoy©) Data
asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
asco 2016 pembrolizumab medipaper medical communications

ASCO16 Pembrolizumab (Keytruda©) Data

/wp-content/uploads/2016/05/asco-2016-pembrolizumab.jpg 851 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-05-29 00:23:322018-05-11 17:22:45ASCO16 Pembrolizumab (Keytruda©) Data
asco 2016 immune checkpoint inhibitors

ACC2016: 8½ Important Cardiology Lessons Learned

/wp-content/uploads/2016/04/acc2016-chicago-take-away-messages.jpg 1672 2508 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2016-04-04 22:11:202017-11-25 14:09:33ACC2016: 8½ Important Cardiology Lessons Learned
PreviousNext
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | Medical Communications Health Blog | Medical Writer Jobs
© 2016-2018 MediPaper Medical Communications Ltd | Medical Writer Hong Kong | 醫學寫作 | 醫學作家香港 | Privacy Policy | Terms of Service | Cookie Policy
  • Twitter
  • Linkedin
  • Facebook
  • Gplus
  • Mail
  • Rss
AMNOG: Germany Pharmaceuticals Pricing Legislation Overview AMNOG Germany Pharmaceuticals Pricing Legislation MediPaper Medical Writer Hong Kong adjuvant hormonal therapy Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive...
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com

Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds: